Clinical characteristics of patients with mantle cell lymphoma

Authors

  • Daniel Ricardo Martínez Avila Instituto Nacional de Oncología y Radiobiología
  • Elías Antonio Gracia Medina
  • Brenda Benítez Caballero
  • Kandecy Archer-Austin
  • Tamara González Madruga
  • Julio Jiménez Galaimena
  • Dagmar Alfonso Estévez
  • Danoy Sanchez Pérez
  • Danay Corrales Otero
  • Encamación Vásquez Olazabal

Abstract

Introduction: Mantle cell lymphoma represents less than 10% of all non-Hodgkin lymphomas. It is characterized by aggressive behavior.

Objective: Describe the clinicopathological characteristics of patients diagnosed with mantle cell lymphoma.

Methods: An observational retrospective study was conducted of 40 patients diagnosed with mantle cell lymphoma attending the Institute of Oncology and Radiobiology from 2008 to 2019. The variables considered were demographic characteristics of patients, disease features at diagnosis and treatment indicated. Overall survival was estimated with the Kaplan-Meier method.

Results: Mean age at diagnosis was 62 years. Of the patients studied, 55.0% were female. According to Ann Arbor staging, 20% and 50% were at clinical stage III and IV, respectively. 40% presented extranodal involvement in the digestive system. 25% received rituximab-related regimens, of which 42.5% were cytarabine-based. Complete response was achieved in 77.5% of the cases after induction therapy. Overall survival was 46.3% at 5 years.

Conclusions: Mantle cell lymphoma is an infrequent condition. In most cases it is diagnosed at advanced stages, with extranodal damage. High response rates are obtained with induction therapy.

Key words: mantle cell lymphoma; non-Hodgkin lymphoma; immunotherapy; chemotherapy.

Downloads

Download data is not yet available.

Author Biography

Daniel Ricardo Martínez Avila, Instituto Nacional de Oncología y Radiobiología

Especialista en 1er Grado en MGI y Oncologia. Profesor Asistente. Investigador Agregado. Servicio de Oncologia Medica, INOR.

References

1.Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. ESMO Guidelines Committee. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv62-iv71. doi: 10.1093/annonc/mdx223.

2. Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016 Feb 20;387(10020):770-8. doi: 10.1016/S0140-6736(15)00667-4.

3. Maddocks K. Update on mantle cell lymphoma. Blood. 2018 Oct 18;132(16):1647-1656. doi: 10.1182/blood-2018-03-791392.

4. McKay P, Leach M, Jackson B, Robinson S, Rule S. Guideline for the management of mantle cell lymphoma. Br J Haematol. 2018 Jul;182(1):46-62. doi: 10.1111/bjh.15283.

5. Nodit L, Bahler DW, Jacobs SA, Locker J, Swerdlow SH. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol. 2003 Oct;34(10):1030-4. doi: 10.1053/s0046-8177(03)00410-6.

6. Cheah CY, Seymour JF, Wang ML. Mantle Cell Lymphoma. J ClinOncol. 2016 Apr 10;34(11):1256-69. doi: 10.1200/JCO.2015.63.5904.

7. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms.Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569.

8. Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016 Aug 6;388(10044):565-75. doi: 10.1016/S0140-6736(16)00739-X.

9. Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016 Nov;175(3):410-418. doi: 10.1111/bjh.14241.

10. Cheah CY, Seymour JF, Wang ML. Mantle Cell Lymphoma. J ClinOncol. 2016 Apr 10;34(11):1256-69. doi: 10.1200/JCO.2015.63.5904.

11. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971 Nov;31(11):1860-1. PMID: 5121694.

12. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Spech LT, Horning SJ, et al. Revised response criteria for malignant lymphoma. J ClinOncol. 2007;25(5):579-86. doi: 10.1200/JCO.2006.09.2403.

13. Castellino A, Tun AM, Wang Y, Habermann TM, King RL, Ristow KM, et al. Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma. Blood Cancer J. 2021 Jan 7;11(1):8. doi: 10.1038/s41408-020-00394-z.

14. Abrisqueta P, Scott DW, Slack GW, Steidl C, Mottok A, Gascoyne RD, et al. Observation as the initial management strategy in patients with mantle cell lymphoma. Ann Oncol. 2017 Oct 1;28(10):2489-2495. doi: 10.1093/annonc/mdx333.

15. Sorigue, M., Sancho, J.-M., García, O., Vila, J., Moreno, M., & Ribera, J.-M. Linfoma de células del manto. Respuesta al tratamiento y pronóstico en 45 pacientes. Medicina Clínica 2016; 147(1), 18–21. doi:10.1016/j.medcli.2016.03.0

16. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. European Mantle Cell Lymphoma Network. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.Blood. 2008 Jan 15;111(2):558-65. doi: 10.1182/blood-2007-06-095331.

17. Morello L, Rattotti S, Giordano L, Jerkeman M, Meerten T, Krawczyk K. Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study. Hemasphere. 2020 Feb; 4(1): e302. doi: 10.1097/HS9.0000000000000302

18. Dabaja BS, Zelenetz AD, Ng AK, Tsang RW, Qi S, Allen PK, et al. Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG). Ann Oncol. 2017;28(9):2185–90.doi: 10.1093/annonc/mdx334.

19. Yang X, Khoo LP, Chang EWY, Yang VS, Poon E, Somasundaram N,et al. Treatment patterns and outcomes of older patients with mantle cell lymphoma in an Asian population. BMC Cancer 2021; 21(1): 566. doi: 10.1186/s12885-021-08326-1

20. Enciso LJ, Suarez ML, Arango M. Resultados del tratamiento del linfoma de células del manto con varios regímenes de inmunoquimioterapia: estudio retrospectivo. RevColombCancerol. 2015;19(2):71-81.Disponible en: https://www.revistacancercol.org/index.php/cancer/article/view/300

21. Campbell J, Hurtado S, Kutz C, Soto K, Ernst D.Resultados de pacientes con linfoma del manto: impacto de terapias basadas en citarabina y trasplante hematopoyético. Rev. méd. Chile [Internet]. 2019 [citado 2021 Ago 06]; 147(1): 9-17. doi:10.4067/S0034-98872019000100009

22. Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, et al. Immunochemotherapy With rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99(9):706–14.doi: 10.1093/jnci/djk152.

23. Lee M-Y, Tan T-D, Feng A-C, Liu M-C. Clinicopathological analysis of 598 malignant lymphomas in Taiwan: seven-year experience in a single institution. Am J Hematol. 2006;81(8):568–75.doi: 10.1002/ajh.20649.

24. Kang BW, Sohn SK, Moon JH, Chae YS, Kim JG, Lee SJ, et al. Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: study by the consortium for improving survival of lymphoma. Blood Res. 2014;49(1):15.doi: 10.5045/br.2014.49.1.15.

Downloads

Published

2021-10-05

How to Cite

1.
Martínez Avila DR, Gracia Medina EA, Benítez Caballero B, Archer-Austin K, González Madruga T, Jiménez Galaimena J, et al. Clinical characteristics of patients with mantle cell lymphoma. Rev Cub Oncol [Internet]. 2021 Oct. 5 [cited 2025 Jun. 25];19(3). Available from: https://revoncologia.sld.cu/index.php/onc/article/view/152

Issue

Vol. 19 No. 3 (2021): septiembre - diciembre

Section

Artículos Originales

License

Esta revista provee acceso libre e inmediato a su contenido bajo el principio de que hacer disponible gratuitamente la investigación al público apoya a un mayor intercambio de conocimiento global.

Esto significa que se permite su copia y distribución por cualquier medio siempre que mantenga el reconocimiento de sus autores, no haga uso comercial de las obras y no realice ninguna modificación de ellas.

El envío de manuscritos, el procesamiento y la publicación no ofrece ningún coste a los autores, es totalmente gratis.